Benson Hill Announces Third Quarter 2022 Financial Results and Raises 2022 Guidance
Benson Hill, Inc. (NYSE: BHIL) reported a significant revenue increase of 307% year-over-year, reaching $130 million for Q3 2022, primarily driven by a 429% surge in its Ingredients segment. The company raised its 2022 revenue guidance to $430 million to $455 million, with expected gross profits of $14 million to $17 million. Despite a net loss of $30.2 million, management aims for positive EBITDA by 2025. The Fresh segment witnessed a 11% revenue decline due to adverse weather conditions. The company is also pursuing strategic options for its Fresh business.
- Consolidated revenues increased 307% year-over-year to $130 million.
- Ingredients segment revenues rose 429% to $122.3 million.
- Management raised 2022 revenue guidance to $430 million to $455 million.
- Gross profit guidance improved to $14 million to $17 million.
- Net loss of $30.2 million in Q3 2022
- Fresh segment revenues declined 11% due to weather-related issues.
- Adjusted EBITDA loss of $17.5 million.
-
Consolidated revenues increased 307 percent year-over-year to
driven by a 429 percent increase in Ingredients segment revenues.$130 million -
Management raised 2022 guidance with consolidated revenues in the range of
to$430 million and gross profit of$455 million to$14 million .$17 million - Management has taken actions intended to fully fund the business to expected positive EBITDA and free cash flow in 2025.
“Our team members delivered another quarter of impressive results, which positions
Third Quarter Results Compared to the Same Period of 2021
The impact of mark-to-market timing differences on the profit and loss statement and reconciliation of non-GAAP financial measures can be found on pages 7 and 12, respectively.
-
Revenues were
, an increase of$130.2 million , or 307 percent, led by rapid growth in the Ingredients segment, which was partially offset by a decline in revenues in the Fresh segment.$98.2 million -
Gross profit was
, an increase in profitability of$4.4 million due to profit contribution in the Ingredients segment, which was partially offset by a gross loss in the Fresh segment. The results included a$4.0 million gain related to unrealized mark-to-market timing differences.$1.4 million -
Operating expenses were
, a decrease of$32.5 million , which included$6.1 million for non-cash items. The decline was primarily driven by one-time public company expenses incurred in 2021, which were partially offset by increased staffing and related expenses in the current quarter to support Benson Hill’s rapid growth.$8.1 million -
Inclusive of the mark-to-market timing differences, the reported net loss and Adjusted EBITDA were
and$30.2 million , respectively.$17.5 million -
Cash and marketable securities on hand were
as of$192.9 million Sept. 30, 2022 .
Ingredients Segment
-
Revenues for the segment were
, an increase of$122.3 million , or 429 percent. Proprietary soy revenues were$99.1 million , an increase of approximately 300 percent. The increase in revenues was mostly driven by the enablement of the closed-loop business model for sales of proprietary and non-proprietary soy and yellow pea ingredient and achievement of better-than-expected throughput capacity at the$26.0 million Creston, Iowa andSeymour, Indiana soy facilities acquired in the prior year. -
Gross profit was
, which includes$5.9 million for unrealized gains related to mark-to-market timing differences to offset unrealized losses incurred in the first quarter. Robust operating performance in the quarter was the result of top line growth of proprietary and non-proprietary products as well as recognition of modest, high-margin revenue contribution from the strategic partnership with$1.4 million ADM . -
Inclusive of the mark-to-market timing differences, Adjusted EBITDA for the segment was a loss of
, a$0.3 million improvement.$5.0 million
Fresh Segment
-
Revenues for the segment were
, a decrease of$7.9 million , or 11 percent due to adverse weather conditions in$0.9 million Florida andGeorgia during the quarter. -
Gross loss was
as a result of weather-related challenges that required high cost purchases of fresh produce to meet contract obligations.$1.6 million -
Adjusted EBITDA was a loss of
, which was a decrease of$2.9 million .$0.5 million
First Nine-Months Results Compared to the Same Period of 2021
-
Revenues were
, an increase of$333.4 million , or 222 percent, led by robust growth in the Ingredients segment.$229.9 million -
Ingredients segment revenues were
, an increase of$281.9 million , or 369 percent. Proprietary revenues were$221.8 million , an increase of 158 percent.$52.2 million -
Fresh segment revenues were
, an increase of$51.3 million , or 18 percent.$8.0 million
-
Ingredients segment revenues were
-
Gross profit was
, an increase in profitability of$4.7 million , which includes$3.8 million related to the remaining unrealized losses from mark-to-market timing differences in the first quarter. Performance year-to-date was favorably impacted by top line growth, proprietary revenue mix, and contributions from partnership and licensing, which was partially offset by cost pressures in the Ingredients segment supply chain, the second quarter write-down of inventory in the Fresh segment, as well as the impact from adverse weather during the third quarter. When considering the effect of the timing of the mark-to-market adjustments, year-to-date gross profit was$1.6 million .$6.3 million -
Operating expenses were
, an increase of$102.4 million due to higher costs to operate a fast-growing public company. Operating expense includes$18.4 million for non-cash items.$26.7 million -
Inclusive of the mark-to-market timing differences, the reported net loss was
compared to a net loss of$74.3 million . Adjusted EBITDA was a loss of$83.6 million compared to a loss of$60.8 million .$50.8 million -
Ingredients segment Adjusted EBITDA was a loss of
.$16.3 million -
Fresh segment Adjusted EBITDA was loss of
.$1.0 million
-
Ingredients segment Adjusted EBITDA was a loss of
Liquidity
Planned revenue growth and gross margin expansion over the next three years will be the primary means to source the Company’s liquidity. The strategic and operating milestones achieved over the last 12 months validate Benson Hill’s mission and planned objectives in support of its previously stated 2025 financial targets:
-
Consolidated revenue in excess of
, including$500 million or more of proprietary Ingredients revenue;$350 million - Gross profit margin greater than 25 percent; and
- Positive EBITDA and free cash flow.
Management has taken proactive actions intended to fully fund the business, inclusive of debt repayments, to achieve its 2025 strategic and financial objectives. This includes an upfront technology access fee from
As previously announced, the Company initiated a strategic review of the Fresh business earlier this year. As a result, interested parties are in discussions with management to acquire the business and related assets. The Company cannot assure that it will be able to consummate any strategic transaction on favorable or timely terms, if at all. If a transaction or transactions were to occur, the likely result will be a non-cash write-off of up to approximately 50 percent of the book value of the business. Management expects to use the net proceeds from a possible divestiture to further enhance the Company’s liquidity position.
Revised 2022 Outlook
As a result of the continued strong demand for non-proprietary ingredient soy and yellow pea products, management increased the Ingredient segment full-year revenue guidance to
Management raised its gross profit guidance to
The Company improved its guidance to a net loss of
Webcast
A webcast of the earnings conference call will begin at
Use of Non-GAAP Financial Measures
In this press release, the Company includes non-GAAP performance measures. The Company uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company’s historical operating results. The Company’s management believes these non-GAAP measures are useful in evaluating the Company’s operating performance and are similar measures reported by publicly listed
Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures and the Company's definition of these non-GAAP measures is included in the tables accompanying this release.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or the Company’s future financial or operating performance. These forward-looking statements include, among other things, statements regarding: the Company’s currently expected guidance regarding certain full year 2022 and projected 2025 financial results, including consolidated revenues, gross profit, gross profit margin, revenues for its proprietary soy portfolio, segment revenues, operating expense, capital expenditures, net loss, EBITDA, Adjusted EBITDA, cash usage, and free cash flow; expectations regarding actions intended to fully fund the business, inclusive of debt repayments, to achieve the Company’s 2025 strategic and financial objectives; the sufficiency of the Company’s cash position and planned capital generating activities to fund the business in future periods; the anticipated benefits of the Company’s ATM facility; the anticipated benefits and other aspects of the Company’s strategic partnership with
Material Items Included in Consolidated Revenues and Cost of Sales
(In Thousands)
Currently, the Company does not seek cash flow hedge accounting treatment for its derivative financial instruments and thus changes in fair value are reflected in current earnings.
Mark-to-market timing difference comprises the estimated net temporary impact resulting from unrealized period-end gains/losses associated with the fair valuation of futures contracts associated with the Company’s committed future operating capacity. These mark-to-market timing differences are not indicative of the Company’s operating performance.
The Company recorded the fair value of acquired sales and purchase contracts in the acquisition of the Company’s
The table below summarizes the pre-tax gains and losses related to derivatives and contract assets and liabilities:
|
Nine Months Ended |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
Open Mark-to-Market Timing Differences |
||||||||||||||||||
|
YTD Reported |
|
Q1 Impact |
|
Q2 Impact |
|
Q3 Impact |
|
YTD Impact |
|
YTD Excluding |
||||||||||
Revenues |
$ |
333,371 |
|
|
$ |
(5,002 |
) |
|
$ |
3,885 |
|
$ |
3,267 |
|
$ |
2,150 |
|
|
$ |
331,221 |
|
Ingredients Segment |
|
281,894 |
|
|
|
(5,002 |
) |
|
|
3,885 |
|
|
3,267 |
|
|
2,150 |
|
|
|
279,744 |
|
Fresh Segment |
|
51,318 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
51,318 |
|
Unallocated Other |
|
159 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
159 |
|
Gross profit |
$ |
4,721 |
|
|
$ |
(8,181 |
) |
|
$ |
5,227 |
|
$ |
1,381 |
|
$ |
(1,573 |
) |
|
$ |
6,294 |
|
Total operating expenses |
$ |
102,416 |
|
|
$ |
— |
|
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
|
$ |
102,416 |
|
Reported net loss |
$ |
(74,299 |
) |
|
$ |
(8,181 |
) |
|
$ |
5,227 |
|
$ |
1,381 |
|
$ |
(1,573 |
) |
|
$ |
(72,726 |
) |
Adjusted EBITDA |
$ |
(60,826 |
) |
|
$ |
(8,181 |
) |
|
$ |
5,227 |
|
$ |
1,381 |
|
$ |
(1,573 |
) |
|
$ |
(59,253 |
) |
-
First quarter of 2022: The net temporary unrealized period-end loss on revenues and cost of sales was
and$5.0 million , respectively. The amortization of acquired sales and purchase contracts was$3.2 million .$0.6 million
-
Second quarter of 2022: The net temporary unrealized period-end gain on revenues and cost of sales was
and$3.9 million , respectively. Management expects the remaining unrealized period-end loss of$1.3 million to reverse in the coming quarters.$2.9 million
-
Third quarter of 2022: The net temporary unrealized period-end gain on revenues and loss on cost of sales was
and$3.3 million , respectively. Management expects the remaining unrealized period-end loss of$1.9 million to reverse by the end of 2022.$1.6 million
- See Adjusted EBITDA reconciliation on page 12.
Condensed Consolidated Balance Sheets (In Thousands) |
|||||
|
|
|
|
||
|
2022 |
|
2021 |
||
|
(Unaudited) |
|
|
||
Assets |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
29,978 |
|
$ |
78,963 |
Marketable securities |
|
162,939 |
|
|
103,689 |
Accounts receivable, net |
|
38,213 |
|
|
31,729 |
Inventories, net |
|
42,575 |
|
|
48,724 |
Prepaid expenses and other current assets |
|
11,786 |
|
|
20,253 |
Total current assets |
|
285,491 |
|
|
283,358 |
Property and equipment, net |
|
126,211 |
|
|
126,885 |
Right of use asset, net |
|
72,882 |
|
|
77,452 |
|
|
42,148 |
|
|
42,664 |
Other assets |
|
4,545 |
|
|
4,538 |
Total assets |
$ |
531,277 |
|
$ |
534,897 |
|
|
|
|
||||
|
2022 |
|
2021 |
||||
|
(Unaudited) |
|
|
||||
Liabilities and stockholders’ equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
26,451 |
|
|
$ |
35,508 |
|
Revolving line of credit |
|
— |
|
|
|
47 |
|
Current lease liability |
|
3,352 |
|
|
|
2,422 |
|
Current maturities of long-term debt |
|
3,173 |
|
|
|
6,934 |
|
Accrued expenses and other current liabilities |
|
29,918 |
|
|
|
26,771 |
|
Total current liabilities |
|
62,894 |
|
|
|
71,682 |
|
Long-term debt |
|
106,507 |
|
|
|
77,170 |
|
Long-term lease liability |
|
79,531 |
|
|
|
79,154 |
|
Warrant liabilities |
|
29,556 |
|
|
|
46,051 |
|
Conversion option liability |
|
10,207 |
|
|
|
8,783 |
|
Deferred tax liabilities |
|
297 |
|
|
|
294 |
|
Other non-current liabilities |
|
184 |
|
|
|
316 |
|
Total liabilities |
|
289,175 |
|
|
|
283,450 |
|
Stockholders’ equity: |
|
|
|
||||
Redeemable convertible preferred stock, |
|
— |
|
|
|
— |
|
Common stock, |
|
21 |
|
|
|
18 |
|
Additional paid-in capital |
|
605,884 |
|
|
|
533,101 |
|
Accumulated deficit |
|
(354,868 |
) |
|
|
(280,569 |
) |
Accumulated other comprehensive loss |
|
(8,935 |
) |
|
|
(1,103 |
) |
Total stockholders’ equity |
|
242,102 |
|
|
|
251,447 |
|
Total liabilities and stockholders’ equity |
$ |
531,277 |
|
|
$ |
534,897 |
|
Condensed Consolidated Statements of Operations (Unaudited) (In Thousands, Except Per Share Information) |
|||||||||||||||
|
Three Months
|
|
Nine Months
|
||||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Revenues |
|
130,179 |
|
|
|
32,000 |
|
|
|
333,371 |
|
|
|
103,494 |
|
Cost of sales |
|
125,812 |
|
|
|
31,591 |
|
|
|
328,650 |
|
|
|
102,546 |
|
Gross profit (loss) |
|
4,367 |
|
|
|
409 |
|
|
|
4,721 |
|
|
|
948 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Research and development |
|
11,433 |
|
|
|
10,458 |
|
|
|
35,756 |
|
|
|
26,403 |
|
Selling, general and administrative expenses |
|
21,042 |
|
|
|
28,076 |
|
|
|
66,660 |
|
|
|
57,570 |
|
Total operating expenses |
|
32,475 |
|
|
|
38,534 |
|
|
|
102,416 |
|
|
|
83,973 |
|
Loss from operations |
|
(28,108 |
) |
|
|
(38,125 |
) |
|
|
(97,695 |
) |
|
|
(83,025 |
) |
Other (income) expense: |
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
6,278 |
|
|
|
1,498 |
|
|
|
16,190 |
|
|
|
4,033 |
|
Loss on extinguishment of debt |
|
— |
|
|
|
11,742 |
|
|
|
— |
|
|
|
11,742 |
|
Change in fair value of warrants |
|
(4,035 |
) |
|
|
(15,244 |
) |
|
|
(41,676 |
) |
|
|
(12,525 |
) |
Other expense (income), net |
|
(195 |
) |
|
|
(2,065 |
) |
|
|
2,060 |
|
|
|
(2,453 |
) |
Total other (income) expense, net |
|
2,048 |
|
|
|
(4,069 |
) |
|
|
(23,426 |
) |
|
|
797 |
|
Net loss before income tax |
|
(30,156 |
) |
|
|
(34,056 |
) |
|
|
(74,269 |
) |
|
|
(83,822 |
) |
Income tax expense (benefit) |
|
13 |
|
|
|
218 |
|
|
|
30 |
|
|
|
218 |
|
Net loss |
$ |
(30,169 |
) |
|
$ |
(34,274 |
) |
|
$ |
(74,299 |
) |
|
$ |
(84,040 |
) |
Net loss per common share: |
|
|
|
|
|
|
|
||||||||
Basic and diluted loss per common share |
$ |
(0.16 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.42 |
) |
|
$ |
(0.71 |
) |
Weighted average shares outstanding: |
|
|
|
|
|
|
|
||||||||
Basic and diluted weighted average shares outstanding |
|
186,097 |
|
|
|
118,709 |
|
|
|
177,539 |
|
|
|
117,714 |
|
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (In Thousands) |
|||||||||||||||
|
Three Months
|
|
Nine Months
|
||||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Net loss |
$ |
(30,169 |
) |
|
$ |
(34,274 |
) |
|
$ |
(74,299 |
) |
|
$ |
(84,040 |
) |
Foreign currency: |
|
|
|
|
|
|
|
||||||||
Comprehensive loss |
|
(1 |
) |
|
|
31 |
|
|
|
(46 |
) |
|
|
30 |
|
|
|
(1 |
) |
|
|
31 |
|
|
|
(46 |
) |
|
|
30 |
|
Marketable securities: |
|
|
|
|
|
|
|
||||||||
Comprehensive (loss) income |
|
(1,759 |
) |
|
|
(121 |
) |
|
|
(9,918 |
) |
|
|
150 |
|
Adjustments for net income (losses) realized in net loss |
|
(97 |
) |
|
|
144 |
|
|
|
2,132 |
|
|
|
(203 |
) |
Total other comprehensive (loss) income |
|
(1,857 |
) |
|
|
54 |
|
|
|
(7,832 |
) |
|
|
(23 |
) |
Total comprehensive loss |
$ |
(32,026 |
) |
|
$ |
(34,220 |
) |
|
$ |
(82,131 |
) |
|
$ |
(84,063 |
) |
Condensed Consolidated Statements of Cash Flows (Unaudited) (In Thousands) |
|||||||
|
Nine Months Ended |
||||||
|
2022 |
|
2021 |
||||
Operating activities |
|
|
|
||||
Net loss |
$ |
(74,299 |
) |
|
$ |
(84,040 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Depreciation and amortization |
|
16,504 |
|
|
|
8,460 |
|
Stock-based compensation expense |
|
15,771 |
|
|
|
2,769 |
|
Bad debt expense |
|
724 |
|
|
|
184 |
|
Change in fair value of warrants and conversion option |
|
(41,676 |
) |
|
|
(12,525 |
) |
Accretion and amortization related to financing activities |
|
8,481 |
|
|
|
1,329 |
|
Loss on extinguishment of debt |
|
— |
|
|
|
11,742 |
|
Other |
|
6,312 |
|
|
|
1,766 |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
(7,208 |
) |
|
|
2,492 |
|
Inventories |
|
6,441 |
|
|
|
(5,450 |
) |
Prepaid expenses and other current assets |
|
8,052 |
|
|
|
(7,567 |
) |
Accounts payable |
|
(6,093 |
) |
|
|
3,917 |
|
Accrued expenses |
|
2,604 |
|
|
|
3,340 |
|
Net cash used in operating activities |
|
(64,387 |
) |
|
|
(73,583 |
) |
Investing activities |
|
|
|
||||
Purchases of marketable securities |
|
(350,333 |
) |
|
|
(100,278 |
) |
Proceeds from maturities of marketable securities |
|
109,514 |
|
|
|
2,155 |
|
Proceeds from sales of marketable securities |
|
170,217 |
|
|
|
198,195 |
|
Payments for acquisitions of property and equipment |
|
(11,835 |
) |
|
|
(26,603 |
) |
Payment made in connection with business acquisitions |
|
(1,044 |
) |
|
|
(10,853 |
) |
Net cash (used in) provided by investing activities |
|
(83,481 |
) |
|
|
62,616 |
|
Financing activities |
|
|
|
||||
Net contributions from Merger and PIPE financing, net of transaction costs (of |
|
80,825 |
|
|
|
285,378 |
|
Payments for extinguishment of debt |
|
— |
|
|
|
(43,082 |
) |
Principal payments on debt |
|
(6,736 |
) |
|
|
(3,917 |
) |
Proceeds from issuance of debt |
|
24,040 |
|
|
|
19,816 |
|
Borrowing under revolving line of credit |
|
18,970 |
|
|
|
20,464 |
|
Repayments under revolving line of credit |
|
(19,017 |
) |
|
|
(20,464 |
) |
Repayments of financing lease obligations |
|
(1,103 |
) |
|
|
(600 |
) |
Payment of deferred offering costs |
|
— |
|
|
|
— |
|
Net Settlement for withholding taxes upon delivery of equity-based awards |
|
— |
|
|
|
— |
|
Proceeds from the exercise of stock options and warrants |
|
1,950 |
|
|
|
635 |
|
Net cash provided by financing activities |
|
98,929 |
|
|
|
258,230 |
|
Effect of exchange rate changes on cash |
|
(46 |
) |
|
|
30 |
|
Net (decrease) increase in cash and cash equivalents |
|
(48,985 |
) |
|
|
247,293 |
|
Cash and cash equivalents, beginning of period |
|
78,963 |
|
|
|
9,743 |
|
Cash and cash equivalents, end of period |
$ |
29,978 |
|
|
$ |
257,036 |
|
|
|
||||||
|
Nine Months Ended |
||||||
|
2022 |
|
2021 |
||||
Supplemental disclosure of cash flow information |
|
|
|
||||
Cash paid for taxes |
$ |
1 |
|
|
$ |
30 |
|
Cash paid for interest |
$ |
9,864 |
|
|
$ |
4,782 |
|
Supplemental disclosure of non-cash activities |
|
|
|
||||
Issuance of stock warrants |
$ |
— |
|
|
$ |
4,551 |
|
Conversion of warrants upon Merger |
$ |
— |
|
|
$ |
4,576 |
|
Warrants acquired in Merger |
$ |
— |
|
|
$ |
50,850 |
|
Merger transaction costs included in accrued expenses and other current liabilities |
$ |
— |
|
|
$ |
4,231 |
|
Business acquisition purchase price included in accrued expense and other current liabilities |
$ |
— |
|
|
$ |
3,714 |
|
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities |
$ |
2,710 |
|
|
$ |
4,123 |
|
Purchases of inventory included in accounts payable, accrued expenses and other current liabilities |
$ |
292 |
|
|
$ |
— |
|
Financing leases commencing in the period |
$ |
806 |
|
|
$ |
735 |
|
Supplemental Schedules - Segment Information and Non-GAAP Reconciliation
(Dollar Amounts in Thousands)
The Company defines and calculates Adjusted EBITDA as consolidated net loss before net interest expense, income tax provision, and depreciation and amortization, further adjusted to exclude stock-based compensation, other income and expense, and the impact of significant non-recurring items.
Three Months Ended |
Revenue |
|
Adjusted EBITDA |
|||
Ingredients |
|
122,276 |
|
|
(280 |
) |
Fresh |
|
7,883 |
|
|
(2,938 |
) |
Unallocated and other |
|
20 |
|
|
(14,252 |
) |
Total segment results |
$ |
130,179 |
|
$ |
(17,470 |
) |
Adjustments to reconcile consolidated net loss to Adjusted EBITDA:
Consolidated net loss |
(30,169 |
) |
|
Interest expense, net |
6,278 |
|
|
Income tax expense (benefit) |
13 |
|
|
Depreciation and amortization |
5,523 |
|
|
Stock-based compensation |
4,412 |
|
|
Other expense (income), net |
(195 |
) |
|
Change in fair value of warrants and conversion option |
(4,035 |
) |
|
Other nonrecurring costs, including acquisition, transaction, and integration costs |
403 |
|
|
Non-recurring SOX readiness costs |
60 |
|
|
Severance expense |
240 |
|
|
Total Adjusted EBITDA |
(17,470 |
) |
Three Months Ended |
Revenue |
|
Adjusted EBITDA |
|||
Ingredients |
|
23,129 |
|
|
(5,292 |
) |
Fresh |
|
8,812 |
|
|
(2,402 |
) |
Unallocated and other |
|
59 |
|
|
(12,450 |
) |
Total segment results |
$ |
32,000 |
|
$ |
(20,144 |
) |
Adjustments to reconcile consolidated net loss to Adjusted EBITDA:
Consolidated net loss |
(34,274 |
) |
|
Interest expense, net |
1,498 |
|
|
Income tax (expense) benefit |
218 |
|
|
Depreciation and amortization |
3,030 |
|
|
Stock-based compensation |
1,413 |
|
|
Other expense (income), net |
(2,065 |
) |
|
Change in fair value of warrants |
(15,244 |
) |
|
Other non-recurring costs, including acquisition costs |
741 |
|
|
Loss on Extinguishment of debt |
11,742 |
|
|
Merger transaction costs |
11,693 |
|
|
Non-recurring public company readiness costs |
1,104 |
|
|
Total Adjusted EBITDA |
(20,144 |
) |
Nine Months Ended |
Revenue |
|
Adjusted
|
|||
Ingredients |
|
281,894 |
|
|
(16,319 |
) |
Fresh |
|
51,318 |
|
|
(1,014 |
) |
Unallocated and other |
|
159 |
|
|
(43,495 |
) |
Total segment results |
$ |
333,371 |
|
$ |
(60,828 |
) |
Adjustments to reconcile consolidated net loss to Adjusted EBITDA:
Consolidated net loss |
|
(74,299 |
) |
Interest expense, net |
|
16,190 |
|
Income tax (benefit) expense |
|
30 |
|
Depreciation and amortization |
|
16,504 |
|
Stock-based compensation |
|
15,771 |
|
Other expense (income), net |
|
2,060 |
|
Change in fair value of warrants and conversion options |
|
(41,674 |
) |
Other nonrecurring costs, including acquisition, transaction, and integration costs |
|
516 |
|
Non-recurring SOX readiness costs |
|
342 |
|
Severance expense |
|
529 |
|
Fresh segment crop failure costs |
|
1,567 |
|
|
|
705 |
|
Fresh segment restructuring expenses |
|
933 |
|
Total Adjusted EBITDA |
$ |
(60,826 |
) |
Nine Months Ended |
Revenue |
|
Adjusted
|
|||
Ingredients |
|
60,048 |
|
|
(18,489 |
) |
Fresh |
|
43,282 |
|
|
(2,574 |
) |
Unallocated and other |
|
164 |
|
|
(29,702 |
) |
Total segment results |
$ |
103,494 |
|
$ |
(50,765 |
) |
Adjustments to reconcile consolidated net loss to Adjusted EBITDA:
Consolidated net loss |
|
(84,040 |
) |
Depreciation and amortization |
|
8,460 |
|
Stock-based compensation |
|
2,769 |
|
Other expense (income), net |
|
(2,453 |
) |
Change in fair value of warrants and conversion options |
|
(12,525 |
) |
Interest expense, net |
|
4,033 |
|
Other nonrecurring items, including acquisition costs |
|
1,268 |
|
|
|
2,805 |
|
Non-recurring public company readiness costs |
|
5,265 |
|
Income tax expense |
|
218 |
|
Total Adjusted EBITDA |
$ |
(50,765 |
) |
Supplemental Schedules – 2022 Non-GAAP Reconciliation (Dollar Amounts in Thousands) |
|
Adjustments to reconcile estimated 2022 consolidated net loss to estimated Adjusted EBITDA: |
|
|
2022 Estimate |
Consolidated net loss |
|
Interest expense, net |
24,000 |
Depreciation and amortization |
22,000 |
Stock-based compensation |
20,000 |
Other non-recurring costs |
(35,000) |
Total Adjusted EBITDA |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005412/en/
Investors:
Media:
Source:
FAQ
What were the Q3 2022 financial results for BHIL?
What is the revised revenue guidance for BHIL in 2022?
How did the Ingredients and Fresh segments perform in Q3 2022?